Operating Cash Flow per Share: A measure of financial performance calculated as operating cash flow, expressed on a per share basis. Calculated as: Cash Flow from Operations / Weighted Average Shares Outstanding (Diluted)
BioCryst Pharmaceuticals, Inc. (BCRX) had Operating Cash Flow per Share of $1.59 for the most recently reported fiscal year, ending 2025-12-31.
| Income Statement Financials | |
$874.84M |
|
$263.86M |
|
$19.07M |
|
$855.76M |
|
$533.85M |
|
$340.99M |
|
$-73.60M |
|
$267.39M |
|
$267.39M |
|
$263.86M |
|
$263.86M |
|
$263.86M |
|
$263.86M |
|
$340.99M |
|
$338.05M |
|
209.89M |
|
218.58M |
|
$1.26 |
|
$1.21 |
|
| Balance Sheet Financials | |
$404.35M |
|
$8.78M |
|
$109.81M |
|
$514.16M |
|
$196.07M |
|
$428.67M |
|
$437.25M |
|
$633.31M |
|
$-119.15M |
|
$-119.15M |
|
$-119.15M |
|
213.06M |
|
| Cash Flow Statement Financials | |
$347.37M |
|
$-13.69M |
|
$-349.93M |
|
$106.32M |
|
$91.34M |
|
$-14.99M |
|
$85.07M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
2.06 |
|
-- |
|
-- |
|
1.39 |
|
-4.05 |
|
97.82% |
|
38.98% |
|
38.98% |
|
38.64% |
|
30.56% |
|
30.16% |
|
$345.45M |
|
-- |
|
-- |
|
-- |
|
1.70 |
|
3.53 |
|
8.19 |
|
44.57 |
|
-221.45% |
|
-221.45% |
|
51.32% |
|
85.25% |
|
$-0.56 |
|
$1.58 |
|
|
Operating Cash Flow per Share |
$1.59 |